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Abstract
Background Loss of muscle mass and strength is a significant comorbidity in patients with chronic obstructive pulmonary
disease (COPD) that limits their quality of life and has prognostic implications but does not affect everyone equally. To identify
mechanisms that may contribute to the susceptibility to a low muscle mass, we investigated microRNA (miRNA) expression,
methylation status, and regeneration in quadriceps muscle from COPD patients and the effect of miRNAs on myoblast prolif-
eration in vitro. The relationships of miRNA expression with muscle mass and strength was also determined in a group of
healthy older men.
Methods We identified miRNAs associated with a low fat-free mass (FFM) phenotype in a small group of patients with COPD
using a PCR screen of 750 miRNAs. The expression of two differentially expressed miRNAs (miR-675 and miR-519a) was
determined in an expanded group of COPD patients and their associations with FFM and strength identified. The association
of these miRNAs with FFM and strength was also explored in a group of healthy community-dwelling older men. As the
expression of the miRNAs associated with FFM could be regulated by methylation, the relative methylation of the H19 ICR
was determined. Furthermore, the proportion of myofibres with centralized nuclei, as a marker of muscle regeneration, in
the muscle of COPD patients was identified by immunofluorescence.
Results Imprinted miRNAs (miR-675 and from a cluster, C19MC which includes miR-519a) were differentially expressed in
the quadriceps of patients with a low fat-free mass index (FFMI) compared to those with a normal FFMI. In larger cohorts,
miR-675 and its host gene (H19) were higher in patients with a low FFMI and strength. The association of miR-519a expression
with FFMI was present in male patients with severe COPD. Similar associations of miR expression with lean mass and strength
were not observed in healthy community dwelling older men participating in the Hertfordshire Sarcopenia Study. Relative
methylation of the H19 ICR was reduced in COPD patients with muscle weakness but was not associated with FFM. In vitro,
miR-675 inhibited myoblast proliferation and patients with a low FFMI had fewer centralized nuclei suggesting miR-675
represses regeneration.
Conclusions The data suggest that increased expression of miR-675/H19 and altered methylation of the H19 imprinting con-
trol region are associated with a low FFMI in patients with COPD but not in healthy community dwelling older men suggesting
that epigenetic control of this loci may contribute to a susceptibility to a low FFMI.
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Introduction
Skeletal muscle is central to all aspects of physical function.
Consequently the loss of muscle mass and strength that ac-
companies a range of chronic diseases impairs the quality of
life of many individuals. Quadriceps muscle wasting1 and
weakness2 are common complications of chronic obstructive
pulmonary disease (COPD) and have been associated with
reduced survival. Loss of muscle mass and function can occur
even in mild COPD,3 yet some patients with severe COPD
maintain muscle mass and function.4 In patients with severe
disease, measures of muscle mass and strength are better
predictors of mortality than FEV1.
1 Pulmonary rehabilitation,
an exercise-based regimen that principally augments muscle
mass and function, is an effective treatment in COPD5,6
highlighting the impact of skeletal muscle on a patient’s
clinical condition.
In healthy adults muscle mass is maintained by balancing
loss (through protein degradation, autophagy and apoptosis)
with synthesis (through protein synthesis and satellite cell
recruitment).7 In patients with chronic disease the relative
rates of these processes are altered such that catabolic
processes outweigh anabolic processes causing muscle loss.
However, individuals are likely to have their own balance of
anabolic and catabolic processes against which the insult of
COPD is superimposed. If the balance of catabolism and
anabolism is variable between individuals, it follows that indi-
viduals will differ in their response to an identical magnitude
of atrophic insult. This suggestion is consistent with the
observation that patients with the same degree of lung
function impairment display a large variation in degree of
muscle wasting. Susceptibility to muscle wasting may result
from influences operating in early life as can be seen from
the increased prevalence of sarcopenia in individuals who
had a low birth weight.8,9
MicroRNAs (miRNAs) are important regulators of cell phe-
notype involved in both normal development and disease.10
We have recently shown that there is a reduction in miR-1
in the quadriceps muscle of COPD patients, associated with
an increase in its target, HDAC4.11 Others have shown that
changes in miRNA are important in atrophy associated with
congenital myopathies,12 maintaining fibre type13 and muscle
adaptation to exercise.14 MiRNAs exported into the circula-
tion are also potential biomarkers for specific disease pheno-
types and for following disease progression.15,16 We have
previously shown that levels of muscle-specific miRNA are el-
evated in the plasma of COPD patients relative to controls.17
As many miRNAs are processed from RNA polymerase II
dependent transcripts, miRNA levels will be affected by
the same mechanisms that control mRNA production, in-
cluding DNA methylation. Consistent with this suggestion,
hypermethylation of the loci for miR-9, -148, and -34c inacti-
vates expression of these miRNAs in cancer cells.18–20 Other
miRNAs are also expressed from imprinted regions of the
genome so expression of one or other allele is suppressed
often by methylation. Indeed two of the largest miRNA clus-
ters in the human genome, one on chromosome 19 (C19MC)
and one of chromosome 14 (C14MC), are imprinted with the
C19MC expressed only from the paternal chromosome21 and
the C14MC expressed from the maternal chromosome.22
Similarly, miR-675 is processed from the maternally expressed
lincRNA, H19. This gene is widely expressed during
development, becomes down regulated in most adult tissues
but is maintained in adult muscle.23 Consistent with a role in
muscle development or maintenance, miR-675 has been
shown to inhibit myoblast proliferation and promote
differentiation.24
Smoking, a primary cause of COPD, is known to modify
DNA methylation through a number of mechanisms includ-
ing the introduction of DNA breaks and nicotine dependent
suppression of DNA methylase (DNMT1) expression
(reviewed in25). Consequently changes in DNA methylation
are likely to contribute to the changes in gene expression in-
cluding that of miRNAs. The extent to which these effects
occur in an individual will be dependent on factors including
the relative activity of the DNA methylation cycle enzymes.
Polymorphisms that lead to reduced activity of the DNA
methylation cycle and hypomethylation of DNA are over-
represented in elite athletes suggestive of a role in muscle
biology.26
The targeted studies we have performed previously have
identified altered miRNA expression in the muscle and
plasma of COPD patients.17,11 This led us to hypothesize that
the miRNA pattern would differ between patients with a low
fat-free mass index (FFMI) and those with a normal FFMI and
that these differences would provide mechanistic insight into
the susceptibility of some individuals with COPD to lose sig-
nificant muscle mass. We compared miRNA expression pro-
files in samples of quadriceps muscle from COPD patients
with a low FFMI and those with a normal FFMI. This analysis
identified miRNAs from two imprinted regions of the ge-
nome, miR-675 (from the maternally imprinted lincRNA
H19) and C19MC miRNAs (from a paternally expressed
cluster) as the most differentially expressed miRNAs. We val-
idated the findings by analyzing the expression of miR-675
and miR-519a and the host gene for miR-675 (H19) in a larger
group of COPD patients and determined their association
with FFMI and strength. As these miRNAs were derived from
imprinted loci we next analysed relative DNA methylation on
the H19 imprinting control region (ICR) in DNA isolated from
the quadriceps of COPD patients. If the differences identified
were just a measure of size rather than susceptibility to a loss
of muscle mass we would have expected the same associa-
tions to exist in a normal population. We therefore deter-
mined the expression of these miRNAs in the quadriceps of
healthy community dwelling older men participating in the
Hertfordshire Sarcopenia Study. Finally to understand the
contribution of regeneration to the difference between low
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FFMI and normal FFMI we determined the proportion of
fibres with centralized nuclei in samples from COPD patients
with a low or normal FFMI.
Materials and methods
Subjects
COPD cohort
Patients with COPD according to the Global Initiative in Ob-
structive Lung Disease (GOLD) guidelines 200427 were en-
rolled from clinics at the Royal Brompton Hospital. Patients
with a diagnosis of heart, renal, or liver failure, a systemic in-
flammatory or metabolic disorder or a moderate/severe ex-
acerbation (i.e. requiring antibiotics, oral steroids, or
hospitalization) in the preceding 4weeks were excluded.
Healthy age-matched controls were recruited by advertise-
ment. All subjects gave written informed consent and the
protocol was approved by the Royal Brompton & Harefield
NHS Trust Research Ethics Committee (Studies 06/Q0404/35
and 06/Q0410/54). Sixteen control subjects were recruited
by local advertisement. A low FFMI was defined as below
16.0 kg/m2. 28
Physiological measurements
COPD subjects in this study form part of a larger well-
phenotyped cohort described by Natanek et al.4 Measure-
ments of lung volume, using plethysmography, carbon mon-
oxide transfer factor, using the single breath technique
(CompactLab, Jaeger, Germany) and post-bronchodilator spi-
rometry were performed according to ATS/ERS guidelines.29
Blood gas tensions were measured in arterialized capillary
earlobe blood. Fat-free mass index was calculated using bio-
electrical impedance (Bodystat 1500, Bodystat, UK) measured
in patients after resting supine for 10min as described previ-
ously.30 Because of the availability of samples, it was not pos-
sible to work on a single set of samples. The physiological
characteristics of the groups analysed are given in Table 1
and Supplementary Tables 1, 2, 4, and 5.
Quadriceps strength was determined by measuring supine
isometric maximal voluntary contraction (MVC) and
unpotentiated Twitch force (TwQ) as described previously30
and exercise capacity measured as 6min walk distance
5min after bronchodilator treatment (ATS 2002 guidelines31)
as described previously. Muscle biopsy was performed by
percutaneous needle biopsy of the vastus lateralis in the
mid-thigh of the leg that strength was tested was performed
under local anaesthesia using the Bergstrom technique.32
Table 1 Patient characteristics of the validation cohort
Control (n=16) Normal FFMI (n=24) Low FFMI (n=24)
Sex (M, F) 7, 9 15, 9 12, 12
Age (years) 66±8 67±7 64±9
Smoking historya (pack-year) 0 (0, 10) 47 (35, 66)*** 39 (24, 48)***
Weighta (kg) 67.1 (61, 74.1) 75.1 (65.3, 83.0) 61.4 (53.5, 65.8)*, †††
BMIa (kg/m2) 24.8 (23.5, 26.2) 26.7 (24.0, 29.7) 21.8 (19.8, 22.9)**, †††
FFMIa (kg/m2) 16.1 (15.3, 17.2) 17.1(16.2, 17.4) 14.5 (13.4, 14.6)***, †††
FEV1
a (% pred) 107.6 (100.6, 112) 42.8 (25.7, 49.6)*** 36.6 (27.6, 45.2)***
RVTLC 35±6 58±8*** 60±8***
TLCOa (% pred) 92.3 (83.0, 98.1) 45.3 (34.8, 54.4)*** 40.6 (26.7, 50.6)***
6min walk (m) 621±84 368±119*** 400±130***
6min walk % pred 126±12 77±24*** 77±24***
pVO2
a (% pred) 99 (88, 111) 51 (42, 65)*** 45 (36, 51)***
SGRQa 2 (0, 8) 53 (43, 60)*** 56 (51, 63)***
Quadriceps MVC (kg) 34.7± 10.6 27.7±9.8 25.7±7.2**
Quadriceps MVC (% pred) 78±19 66± 17* 61±11**
Locomotion timea (min/12 h) 96 (84, 127) 37 (23, 52)*** 44 (26, 64)***
Movement time (as % of 12 h) 23±6 12±6*** 13±4***
Type I fibre % 54.4±18.1 28.7± 12.1*** 27.4±13.2 ***
Type IIA fibre % 41.0±14.0 58.5± 10.6*** 63.6±14.0***
Type IIX fibre % 2.5± 3.5 6.7±8.2 4.8± 4.5
Definitions of abbreviations:
a=Not normally distributed, BMI=body mass index, FFMI= fat-free mass index, FEV1= forced expiratory volume in 1 s, RV= residual vol-
ume, TLC= total lung capacity, TLCO= transfer coefficient of the lung for CO, Pa02 = arterial oxygen partial pressure, PaC02= arterial car-
bon dioxide partial pressure, pred= predicted, MVC=maximal voluntary contraction, SGRQ, St George’s respiratory questionnaire.
Values are means± SD for normally distributed variables and as median (interquartile range) for variables that were not normally distrib-
uted. Significance was calculated by t-test for normally distributed variables and by Mann–Whitney U-test for variables that were not nor-
mally distributed.
*(P < 0.05).
**(P ≤ 0.01).
***(P ≤ 0.001) low FFMI or normal FFMI vs. control.
††(P ≤ 0.01).
†††(P ≤ 0.001) low FFMI vs. normal FFMI.
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Hertfordshire Sarcopenia study cohort
Samples from the Herts Sarcopenia Study study33 were used
in this analysis as an additional control set to determine
whether similar associations existed in a normal healthy
population of older people as those identified in the COPD
cohort and whether there were any associations with birth
weight. Recruitment of this cohort has been described
previously.33 The protocol was approved by the Hertfordshire
Research Ethics Committee (study 07/Q0204/68), and all
participants gave written informed consent. The skeletal
muscle characterization carried out in this study included:
body composition and lean mass by dual energy X ray absorp-
tiometry scanning, hand-grip strength, determined using a
Jamar hydraulic dynamometer, and physical capability deter-
mined as 3m gait speed and ‘6m time to get up and go’ test.
These have been previously described,33 and the data for the
cohort used in this study are shown in Table S3. Muscle
biopsy was performed by percutaneous needle biopsy of
the vastus lateralis under local anaesthesia as described
previously.34
TaqMan® array microRNA cards
The amplified cDNAs were quantified using Human TaqMan®
Array MicroRNA Cards (Cards A and B, V.3.0 Applied
Biosystems) according to the manufacturer’s instructions on
an ABI 7900HT thermocycler. Array cards were run under
the 384 well TaqMan® Low Density Array default thermal-
cycling conditions defined by SDS 2.4 software. Once com-
plete all cards were calibrated to a single control sample
and one detection threshold set across all samples and assays
using RQ manager software. The resultant Ct values were
then exported and normalized to the geometric mean of
U6, RNU44, and RNU48, using the ΔΔ Ct method. As variance
tended to increase with miRNA intensity the data were stan-
dardized by a log transformation.
Assessment of mRNA and miRNA levels
Messenger RNA was extracted and quantified by quantitative
real time PCR (qRTPCR) as described previously35 or using the
allele specific primer kit for RS2075245 (Life Technologies).
PCR values for H19 (obtained from 11 controls, 34 normal
FFMI patients, and 22 low FFMI patients) were normalized
to the geomean of RPLPO and HPRT. Primers were H19:
For-TGCTGCACTTTACAACCACTG,Rev-TGGTGTCTTTGATGTTGG-
GC,Rev-AATTACTTTTATGTCCCCTGTTGACTGG. MicroRNA ex-
pression was analysed in trizol extracted RNA. RNA isolated
muscle was reverse transcribed using MultiScribe™ Reverse
Transcriptase with, Megaplex™ RT Primers (human pools A and
B, Version 3.0, Applied Biosystems) according to the manufac-
turer’s instructions. The reactions were terminated by heat de-
activation at 85°C for 5min and the cDNA stored at 80°C. The
cDNAs were pre-amplified using Megaplex™ PreAmp Primers
(Applied Biosystems) for 12 cycles of 95°C for 15 s and 60°C
for 4min. The reaction was terminated by heating to 99.9°C
for 10min and pre-amplified cDNA diluted by addition of
75μL of 0.1× TE buffer pH 8.0 (Qiagen) and stored at 80°C.
Quantification of single microRNAs using TaqMan® probes
For the quantification of individual microRNAs, custom de-
signed primers and probes were purchased for each test gene
from Applied Biosystems, and amplification was carried out
on cDNA preamplified as described above according to the
manufacturer’s instructions. Each reaction was performed
in duplicate, and the average Ct value normalized to the cor-
responding geometric mean of U6, and RNU44 using the ΔΔ
Ct method. RNA isolated from cells was analysed using single
RT reactions. MiRNAs were quantified in 16 controls, 24 low
FFMI patients, and 24 normal FFMI patients the COPD cohort
and from 67 individuals in the Herts Sarcopenia Study cohort.
Methylation analysis
DNA from muscle biopsies (for 10 controls, 14 normal FFMI
patients, and 15 low FFMI patients) was extracted using the
QIAamp DNA Mini kit (Life Technologies) according to manu-
facturer’s instructions. The two resulting elutions were then
pooled and precipitated. The resuspended DNA was diluted
to 12.5 ng/μL in AFA fiber pre-slit Snap-Cap microtubes
(Covaris, Life Tech) and sheared using a Covaris S220
Focused-ultrasonicator to sonicate the DNA into 200 bp frag-
ments using a pre-set protocol in the SONOLAB 7.2 software
(Covaris, Life Tech). DNA (1μg) was applied to the
MethylMiner Methylated DNA Enrichment kit (Life Tech) ac-
cording to the manufacturer’s instructions. The resulting
methylation enrichment DNA was eluted in 2000mM and
450mM NaCl, which were then concentrated and pooled.
The DNA was then quantified using the Quant-iT PicoGreen
dsDNA (Life Tech) according to manufacturer’s instructions.
The methylation enriched DNA was diluted to 0.1 ng/μL
whilst the original (non-enriched) DNA was diluted to
1 ng/μL; 1.5μl of DNA was amplified in 20μl SYBR reactions
as described for cDNA using primers UBE2B: For-CTCA
GGGGTGGATTGTTGAC, Rev-TGTGGATTCAAAGACCACGA, H19
ICR: For-TTGGTGGAACACACTGTGATCA, Rev-GAGCCGCACC
AGATCTTCAG.
Immunofluorescence
Frozen 10-μm-thick slices from quadriceps muscle biopsies of
both low FFMI (n = 5) and normal FFMI (n = 10) patients
(Supporting Information, Table S5) were fixed in 4% PFA for
10min at room temperature. Following fixation sections were
washed in 1× PBS-T (3× for 3min), prior to incubation in 5%
BSA-PBS-T solution for 30min at room temperature. The sec-
tions were then incubated with anti-laminin 2α antibody
(1:300, AbCam) overnight at 4°C in a humidified chamber.
The primary antibody solution was removed, and the sections
were washed before incubation with anti-rabbit IgG
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conjugated to Alexafluor-658 (1:500, Invitrogen). The sections
were incubated with the secondary antibody for 1 h at room
temperature, then washed and before incubating with a DAPI
solution (1:10 000) for 15min.
Statistical analysis
All gene expression data were log transformed to stabilize var-
iance and produce a normal distribution. To identify groupings
within the data set principal components analysis (PCA) and
hierarchical cluster analysis (HCA) were performed in Aabel
(Gigawiz). The variables for HCA were scaled to unit variance,
distances were calculated based on correlation coefficients,
and groups were defined based on centroid linkage. Correla-
tion analysis was performed using Pearson correlations as-
suming that correlations would be linear (Aabel). Differences
between groups were calculated by Student’s t-test for
normally distributed data (Excel) and by Mann–Whitney
U-test for non-parametric data (Aabel, Gigawiz).
Results
Patient characteristics
miRNA profiles were determined in RNA isolated from the
quadriceps of, seven patients with a low FFMI, seven patients
with a normal FFMI, and seven age-matched controls. All
samples in this analysis were from males, and their physiolog-
ical characteristics are shown in Table S1. Consistent with a
diagnosis of COPD, both the low FFMI and normal FFMI
patient groups had reduced FEV1 and TLCO% of predicted.
Quadriceps strength, physical activity levels, and exercise
performance were all reduced compared to controls. Both
the low FFMI and normal FFMI COPD groups had a lower
mean FFMI than the healthy controls. The low FFMI and
normal FFMI groups did not differ in any characteristic
measured including daily physical activity except, by design,
FFMI, and consequently weight and BMI (Supporting
Information, Table S1). Furthermore, there was no difference
in fibre type proportion between the patient groups
although both the FFMI groups had a lower proportion of
type I fibres than the controls (Supporting Information,
Table S1).
Low FFMI patients are a distinct sub-group of
COPD patients
HCA and PCA, showed that the low FFMI patients formed a
distinct group based on their miRNA profile. PCA but not
HCA was also able to partially segregate normal FFMI patients
and controls; however, there was overlap in these two groups
(Figure 1A and B). This result was confirmed by linear discrim-
inate analysis, which allowed us to correctly assign the entire
low FFMI group, all controls and five of the seven normal
FFMI patients from their PCA scores.
Identification of FFMI associated miRNAs in muscle
To identify miRNAs associated with a low FFMI in COPD, the
expression of individual miRNAs was compared by t-test
between the groups in a pair wise manner. To increase
stringency miRNAs associated with a low FFMI in COPD were
defined as those that were statistically significantly different
between low FFMI patients and controls/normal FFMI
patients but not statistically different between controls and
normal FFMI patients.
Forty-seven low FFMI-associated miRNAs were identified
(Supporting Information, Table S6). Of these only two
miRNAs were increased in low FFMI patients relative to
normal FFMI patients of which miR-675 showed the
greatest fold change of any miRNA (8.5-fold low FFMI vs.
normal FFMI P = 0.008). The remaining 45 miRNAs were
expressed at lower levels in low FFMI compared to normal
FFMI patients. Median expression of all but 2 miRNAs was
lower in low FFMI patients compared to controls. Compari-
son of miRNA expression in low FFMI and normal FFMI pa-
tients relative to controls showed that the median
expression of 17 miRNAs changed in opposing directions
in low FFMI vs. controls (statistically significant) compared
to normal FFMI vs. controls (not statistically significant)
(Figure 1C and Table S6) including miR-675, miR-1 (consis-
tent with our previous study11), and nine miRNAs from a
cluster located on chromosome 19q13.2 (C19MC).
Muscle array validation
To validate the screen, levels of miR-675 and miR-519a
(derived from the C19MC) were quantified in an ex-
panded cohort of muscle samples from patients including
both males and females of all GOLD stages and healthy
controls (controls n = 16, normal FFMI n = 24 and low
FFMI n = 24, freshly prepared cDNA samples from five
normal FFMI, one low FFMI COPD patients, and four con-
trols from the original screen were used in this expanded
study). The physiological characteristics of these groups
are given in Table 1 and showed similar differences to
those of the screen cohort. There was no difference in
the expression of miR-675 between COPD patients (as a
whole group) with controls. However, median miR-675
expression was higher in the low FFMI patients than
either of the other two groups but was significantly dif-
ferent only compared to the controls (low FFMI vs. cont;
P = 0.013, low FFMI vs. normal FFMI; P = 0.027,
Bonferonni corrected P value for significance = 0.016).
There was no difference in the expression of miR-675
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between normal FFMI patients and controls (Figure 2A).
In the patients, miR-675 was inversely correlated with
FFMI (r =0.41, P = 0.004, Figure 2B). Furthermore, miR-
675 was inversely correlated with quadriceps strength
(vs. MVC, r =0.43, P = 0.003, vs. TwQ, r =0.47,
P = 0.001, Figure 2C and D). MiR-675 was not associated
with lung function judged by either FEV1 or TLCO% pre-
dicted. In the controls miR-675 was not associated with
FFMI or quadriceps strength.
There was no difference in the expression of miR-519a
between COPD patients as a whole group with controls.
In the whole cohort (patients and controls together),
consistent with the array, miR-519a was lower in individ-
uals with a low FFMI than in those with a normal FFMI
(P = 0.025, Figure 3A) and weakly correlated with FFMI
(r = 0.24, P = 0.044, Figure 3B). However, miR-519a was
not different between patients with a low FFMI compared
to patients with a normal FFMI. Restricting the analysis to
samples with the original criteria used for patients in the
screen (male GOLD III–IV, n = 27) increased the association
between miR-519a and FFMI (r = 0.48, P = 0.017, Figure
3C). No association between miR-519a and FFMI was
found in female patients with similar disease severity
(n = 13) raising the possibility of a sex-specific effect.
Figure 1 MicroRNA expression in patients with chronic obstructive pulmonary disease. Hierarchical cluster analysis (A) and principal component anal-
ysis (B) of microRNA expression in the quadriceps of low fat-free mass index, normal fat-free mass index patients, and controls show that the low fat-
free mass index group have a distinct pattern of microRNAs compared to normal fat-free mass index patients and controls. Separation between the
normal fat-free mass index and control groups was weaker and had some degree of overlap. (C) Comparison of the median expression of microRNAs
between low fat-free mass index patients and controls and between normal fat-free mass index patients and controls to identify ‘low fat-free mass
index-associated microRNAs’. Median expression of microRNAs in the bottom right hand quadrant is lower in low fat-free mass index patients than
controls (statistically significant) but higher in the normal fat-free mass index patients than controls (not statistically significant) whereas median ex-
pression of the microRNA in the top left hand quarter is higher in low fat-free mass index patients than controls (statistically significant) but lower in
normal fat-free mass index patients than controls (not statistically significant).
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Analysis of a second miRNA from the same locus (miR-518e)
in GOLD III–IV males also showed a positive association of
C19MC miRs with FFMI in these patients (Figure 3D).
H19 linc RNA expression associates with muscle mass and
strength in COPD
As miR-675 is processed from the H19 lincRNA, we deter-
mined the expression of H19. As the cDNAs for the miRNAs
were generated separately from cDNAs for mRNA analysis
and our samples were limited, it was only possible to obtain
overlapping but distinct data sets for miR-675 and H19. This
analysis used samples from 11 controls, 34 NFFMI patients,
and 22 low FFMI patients; 31 samples were included in both
miRNA and mRNA analyses (see Supporting Information,
Table S2 for the physiological characteristics). There was no
difference in H19 expression between the patients and
controls or between the low FFMI and normal FFMI patients
(Figure 4). However, H19 expression was inversely associated
with FFMI in the patients (r =0.39, P = 0.001) and with
quadriceps strength (vs. MVC r =0.44, P< 0.001 and vs.
TwQ r =0.38, P = 0.007). H19 expression was also higher in
those patients defined as weak based on an MVC less than
120% of their BMI (P = 0.01). In those patients in which we
analysed both miRNA and mRNA, expression of miR-675
and H19 showed a positive association (r = 0.49, P = 0.018,
n = 22 patients only and r = 0.47, P = 0.007 n = 31 patients
and controls, Supplementary Figure 1).
Methylation of the H19 locus is associated with muscle
H19 expression and strength in COPD
To determine whether H19 was expressed from one or both
alleles in adult muscle we used allele-specific PCR for the
polymorphism RS2075245, which is in exon 1 of H19, close
Figure 2 MiR-675 is increased in low fat-free mass index chronic obstructive pulmonary disease patients compared to normal fat-free mass index
chronic obstructive pulmonary disease patients and is associated with muscle mass and strength. The expression of miR-675 was determined by
quantitative PCR in samples of quadriceps from the validation cohort of chronic obstructive pulmonary disease patients and controls as described
in Methods. MiR-675 was elevated in patients with a low fat-free mass index compared to controls (P = 0.013, A). In both patients alone and the whole
cohort, miR-675 was correlated with fat-free mass index (r =0.41, P = 0.008 patients alone r =0.35, P = 0.008 patients and controls, B). In the
patients alone miR-675 was correlated with strength both voluntary (MVC, r =0.43, P = 0.003, C) and involuntary (TwQ =0.47, P = 0.001, D)
measurements of strength. Patients are shown as grey circles controls as black circles.
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to miR-675. In this experiment homozygosity or mono-allelic
expression was assumed when there was difference in Cycle
threshold for each of the alleles of four cycles (i.e. when
one allele contributed >94% of the detectable transcript).
In this analysis, expression of a single SNP variant was de-
tected in 60% of the samples whereas expression of both var-
iants was detected in the remaining 40%. Within the
European Caucasian population the A:T allele frequency is
48:52 so that the approximately 50% of individuals are het-
erozygous. Therefore, in the majority of individuals both al-
leles were active in the muscle. However in the subjects in
whom both A and T alleles were detected, one allele contrib-
uted more than 75% of the transcript in all but three cases in-
dicating that one allele was suppressed, probably by
methylation. It was not possible to determine whether the
same was true from homozygous individuals. As these
primers are designed for genotyping and not mRNA quantifi-
cation, to verify that the method quantified H19 RNA, the
expression of each allele was normalized to RPLPO and the
values summed. This value correlated strongly (r = 0.86,
P< 0.001) to our measurements of H19 performed by non-
allele specific PCR (Supplementary Figure 2) indicating that
the approach was valid.
To determine whether methylation regulates H19 expres-
sion in muscle, we used methylated DNA immunoprecipita-
tion (MeDIP) followed by qPCR using muscle samples from
10 healthy controls, 14 normal FFMI patients, and 15 low
FFMI patients. Methylation on the ICR of precipitated H19
DNA was quantified relative to a comparatively
unmethylated gene UBE2B. There was no significant differ-
ence between relative ICR methylation between patients
and controls. Consistent with methylation suppressing H19
expression, the ICR:UBE enrichment ratio was inversely
correlated with H19 expression in the COPD patients
(r =0.498, P = 0.008, Figure 5A). Furthermore, the
ICR/UBE methylation ratio was higher in patients with a
Figure 3 MiR-519a is suppressed in low fat-free mass index individuals compared to normal fat-free mass index individuals. The microRNA expression
was determined by quantitative PCR in samples of quadriceps from the validation cohort of chronic obstructive pulmonary disease patients and con-
trols as described in Methods. In the whole cohort, miR-519a levels were reduced in individuals with a low fat-free mass index compared to individuals
with a normal fat-free mass index (A) and weakly correlated with fat-free mass index (r = 0.29 P = 0.044, B). In GOLD3/4 male patients quadriceps ex-
pression of miR-519a (C) and miR-518e (D) were correlated with fat-free mass index (r = 048, P = 0.01 and r = 0.39, P = 0.025 respectively). Patients are
shown as grey circles controls as black circles.
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normal strength compared to weak patients (P = 0.026, Figure
5B) and correlated with strength (r = 0.45, P = 0.014, Figure 5C)
but not with FFMI. In this cohort of patients H19 correlated
with strength (r =0.45, P = 0.017) but not with FFMI and
was different between patients with normal strength and
weak patients (P = 0.009, Figure 5D). In the controls the asso-
ciation of relative ICR methylation with strength did not reach
statistical significance (r = 0.57, P = 0.084) unless normalized to
FFMI (r = 0.64, P = 0.045, Supplementary Figure 3). Similarly
strength normalized for FFMI was also correlated with ICR
methylation in the patients alone (r = 0.48, P = 0.009 ) and in
the cohort as a whole (r = 0.45, P = 0.004). Methylation of
the C19MC was not determined because these miRNAs are
not expressed in differentiated cells.36,37 As analysis of meth-
ylation in the biopsies would have profiled whole muscle, the
majority of signal would have been from cells that did not ex-
press the miRNA rather than determining the effect of meth-
ylation on expression.
Are miR-675 and miR-519a markers of FFMI in the gen-
eral population?
The association of miR-675 and miR-519a with FFFMI in
COPD raises the possibility that they are markers of muscle
mass in the general population rather than showing an
adaptation to disease. We therefore determined the
expression of both miRs in the quadriceps of a subset of
individuals from the Hertfordshire Sarcopenia Study, which
assessed muscle mass and function in healthy older adults.
In this cohort neither miRNA was associated with FFMI or
strength (measured as grip strength) or with physical
capability marked by 3m walking time and 6m time to
get up and go. Furthermore, there was no association of
the expression of these miRNAs with birth weight. Compar-
ison of the expression of miR-675 and miR-519a in people
with a history of smoking and in non-smokers also showed
no difference.
Figure 4 H19 is increased in low fat-free mass index chronic obstructive pulmonary disease patients compared to normal fat-free mass index chronic
obstructive pulmonary disease patients and is associated with muscle mass and strength. The expression of H19 was determined by quantitative PCR in
samples of quadriceps from the validation cohort of chronic obstructive pulmonary disease patients and controls as described in Methods. H19 not
different between patient groups or controls (A). In patients H19 was correlated with fat-free mass index (r =0.385, P = 0.001, B) and with was cor-
related with quadriceps strength both voluntary (MVC, r =0.44, P< 0.001, C) and involuntary (TwQ =0.38 P = 0.002, D) measurements of strength.
Patients are shown as grey circles controls as black circles.
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Altered regeneration in low FFMI patients
The ability of miR-675 to inhibit C2C12 cell proliferation (as
previously described38 and as shown in supplementary
information) raises the possibility that there is a difference
in muscle regenerative activity in low FFMI patients and nor-
mal FFMI patients. We therefore determined the expression
of MyoD, a marker of satellite cell activation, and the number
centralized nuclei in samples from male patients with GOLD
3/4 COPD, the selection criteria for our original screen. MyoD
was suppressed in the low FFMI patients compared to the
normal FFMI patients (low FFMI = 0.031 ± 0.009 AU, normal
FFMI = 0.041 ± 0.017 AU, P = 0.037, Figure 6A). The low FFMI
patients also had fewer fibres with centralized nuclei indicat-
ing recent regeneration compared to normal FFMI patients
(normal FFMI 6.9 ± 1.1 centralized nuclei/100 fibres vs. low
FFMI 3.2 ± 0.6 centralized nuclei/100 fibres P = 0.036, Figure
6B–D). These findings are consistent with increased muscle
regeneration occurring in normal FFMI patients compared
to low FFMI patients. In patients in which centralized nuclei,
miR-675, and miR-519a were all measured, miR-675 was
higher (low FFMI median was 2.4-fold higher than the normal
FFMI median, P = 0.014) and miR-519a was lower (low FFMI
median was 0.71 times the normal FFMI median, P = 0.008)
in the low FFMI patients than in the normal FFMI patients.
Discussion
The data presented show that a low FFMI and weakness in
COPD patients are associated with increased expression of
miR-675 and H19 in the muscle and that muscle weakness cor-
relates in these patients with relative methylation of the H19
ICR. Furthermore, the expression of miRNAs from the C19MC
is suppressed in the muscle of male patients with a low FFMI
Figure 5 Methylation of the H19 locus is associated with H19 gene expression and strength. Methylated DNA was precipitated using the MeDiP kit as
described in the Methods and input and precipitated DNA was quantified for the H19 ICR and for UBE2. ICR methylation is presented relative to the
methylation of UBE2 (a sparsely methylated DNA region). H19 ICR methylation was inversely proportional to H19 gene expression (A), higher in weak
patients compared to patients with normal strength (B) and correlated with quadriceps strength measured as % predicted (C). H19 expression was
reduced in weak patients compared patients with normal strength (D).
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and associated with FFMI. However, there was no associa-
tion of miRNA expression with FFMI or strength in healthy
individuals from the Herts Sarcopenia Study nor did
smoking affect the expression of the miRNAs, suggesting
that the associations of miRNA with FFMI and strength oc-
cur only on the background of the disease. Finally we con-
firm that there are fewer centralized nuclei in the muscle
of low FFMI patients compared to patients with a normal
FFMI raising the possibility that poor regeneration is con-
tributory to the low FFMI phenotype. Together, these data
indicate that the level of imprinted miRNAs contributes to
the susceptibility to muscle wasting in the context of COPD,
where the disease provides an atrophic stimulus that can
be resisted in individuals to varying extents dependent on
the expression of these miRNAs. The potential mechanisms
by which these miRNAs contribute to the low FFMI pheno-
type are discussed separately below.
miR-675-H19
The H19-IGF-2 imprinted gene cluster is one of the best-
studied imprinted regions.39 In this cluster H19 is expressed
from the maternal chromosome whereas IGF-2 is expressed
from the paternal chromosome with expression of H19
suppressed by methylation of an imprinting centre. H19 is
a long intergenic non-coding RNA the function of which
appears to be to act as a source of miR-675.24,38 The fact
that the observed associations of H19 with strength and
FFMI were not as strong as those of miR-675 is consistent
with this suggestion. Previous studies of miR-675 have
shown that it inhibits cell proliferation and consistent with
this observation we also found that miR-675 could inhibit
C2C12 proliferation. This inhibition of proliferation has
been shown to occur at least in part through suppressing
IGF1R,38 therefore increased miR-675 in myofibres is likely
to suppress hypertrophy.
Figure 6 Reduced regeneration in the muscle of low fat-free mass index patients. (A) sections of muscle were stained for laminin and DAPI as de-
scribed in Methods. The number of centralized nuclei was determined by counting the number of transverse cut fibres with an intact laminin outline
and the number of centralized nuclei in the whole section by an individual blinded to the group assignment of each image. Centralized nuclei are pre-
sented as number per 100 fibres. The number of centralized nuclei was higher in normal fat-free mass index patients than in low fat-free mass index
patients. (C and D) Segments of representative images used in counting the number of centralized nuclei from a normal fat-free mass index patient (C)
and a low fat-free mass index patient (D). White arrows indicate centralized nuclei. (B) MyoD mRNA expression was determined in the quadriceps of
patients with chronic obstructive pulmonary disease as described in Methods. Normal fat-free mass index patients expressed significantly more MyoD
than low FFMI patients (P< 0.05).
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Our data show that H19 and miR-675 are expressed at
low levels in proliferating cells but are markedly elevated
in cells that have stopped proliferating and are differentiat-
ing (see Supporting Information). Recently it has also been
shown that miR-675 promotes myoblast differentiation24
by suppressing expression of SMAD-1 and -5 leading to
reduced BMP signalling as well as a suppression of cdc6
(a protein required for the G1-S phase transition in the cell
cycle). This study suggests three likely consequences of an
elevated background of miR-675 that would contribute to
a low FFMI phenotype. First, in differentiated myofibres
BMP signalling is pro-hypertrophic,40and a reduction in
BMP signalling has been shown to be pro-atrophic.40 Sec-
ond, as the analysis was performed in whole muscle
homogenates we are unable to differentiate between
changes in miR-675 expression in myofibres and satellite
cells. Consequently, if the increase in miR-675 is not re-
stricted to myofibres but is also present in myoblasts and
satellite cells it will inhibit the expansion of the myoblast
pool (by inhibiting cdc6 and reducing cell proliferation),
and third, it will promote the early differentiation of these
cells reducing the time available for myoblast proliferation
and further restricting the pool of cells available for
regeneration.
C19MC miRNAs
The C19 microRNA cluster is the largest cluster of miRNAs
in the human genome but arose relatively late in evolution
and is only found in primates.21 The miRNAs from this clus-
ter are expressed in pluripotent cells and in the placenta
but are not expressed in fully differentiated tissues.36,37 It
therefore seems likely that the transcripts that we detected
arose from satellite cells rather than from the myofibres.
Consistent with this suggestion the levels of C19MC
miRNAs were low. Functionally the C19MC miRNAs have
been shown to promote the pluripotent state in embryonic
stem cells by targeting RBL-2 and thereby relieving RBL-2
dependent suppression of the expression of a methyltrans-
ferase DNMT3B a key regulator of embryonic differentia-
tion.41 Knockdown of DNMT3B results in a reduction in
embryonic stem cell survival and in the formation of em-
bryonic stem cell-derived clones in vitro. These data sug-
gest that C19MC miRNAs may contribute to the normal
FFMI phenotype by promoting stem cell survival.36,37
It is important to note that the association of C19MC ex-
pression with FFMI was only evident in males with severe
COPD. The lack of association of C19MCs in the cohort as a
whole and in other groups individually may be because of
confounding factors and/or statistical power as some of the
sub-groups were relatively small. It is also possible that it is
only apparent in the severe subgroup as, in the absence of
significant physiological stress because of severe disease,
the requirement for regeneration will be limited to normal
muscle cell turnover.
Imprinting and DNA methylation
Both C19MC and H19 expressions are regulated by imprint-
ing.42 The C19MC locus is expressed from the paternal chro-
mosome, whereas H19 is expressed from the maternal
chromosome. In general, paternally imprinted genes pro-
mote growth whereas maternally imprinted genes inhibit
growth, and our data are consistent with this observation.
In muscle, imprinted genes are predominantly expressed in
stem/progenitor cells in adult mice.43 This pattern of expres-
sion is consistent with an important functional role in the
regulation of satellite cells and represents one way in which
imprinted genes may contribute to the control of post-natal
skeletal muscle mass.43 As imprinting involves DNA methyla-
tion the involvement of imprinting suggests that DNA meth-
ylation makes an important contribution to the low FFMI
and normal FFMI phenotypes. Methylation of the H19-IGF-
2 ICR inhibits the expression of H1944 and our data showing
an inverse correlation of H19 expression with relative H19-
IGF-2 ICR methylation is consistent with this observation.
Furthermore, our data showing that relative methylation of
the H19-IGF-2 ICR is higher in normal FFMI patients and is
correlated with muscle strength suggests that differences
in DNA methylation of particular loci may contribute to
the control of muscle function in adulthood in response to
the stress of COPD.
Most studies of imprinted genes focus on development
and the early post-natal period. Consequently the associa-
tion of H19 and miR-675 with muscle mass and strength in
adults has not previously been noted, and we did not find
an association of miR-675 with FFMI or strength in the Herts
Sarcopenia Study participants. This observation suggests
that the association is only present or detectable in patients
with a disease that predisposes to muscle wasting. It is
therefore possible that differences in the expression of this
miRNA are only of functional significance when there is an
increased atrophic drive and/or an increase in the demand
for muscle synthesis.
Reduced regeneration in low FFMI patients
Consistent with the recent studies of Theriault et al.45 who
observed reduced centralized nuclei in patients with a mid
thigh muscle cross-sectional area< 70 cm2 compared to
those with a mid thigh cross-sectional area> 70 cm2 we
found that patients with a low FFMI had reduced proportion
of myofibres with centralized nuclei. This observation implies
that a low level of regeneration contributes to the low FFMI
phenotype. As described above both a low level of expression
of C19MC miRNAs and an increased miR-675 expression may
contribute to this reduction in regeneration.
Critique of the method
The study is cross sectional, and as such the data can only dem-
onstrate associations rather than causation. Nevertheless, our
analysis of the muscle has highlighted a number of miRNAs
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with potential mechanistic relevance to the development of
skeletal muscle dysfunction in COPD that warrant further inves-
tigation. Although one interpretation of our data is that there is
a reduction in the number of satellite cells, we did not quantify
satellite cell number directly because of the number and size of
the samples available. Our analysis of centralized nuclei is con-
sistent with the data of Theriault,45 and in their study they did
not see a difference in satellite cell number between patients
with a low or normal mid thigh cross-sectional area suggesting
that any differences are small. Consequently if there is a differ-
ence in satellite cell number it will require a large number of bi-
opsies to identify it. It is also possible that the number of
satellite cells does not change either because these cells have
become senescent as suggested by Theriault et al. or because
the effects of miR-675 are on the proliferation of committed
myoblasts rather than the number of satellite cells. Whether
any such senescence results from high miR-675 and/or low
C19MC expression remains to be established.
Clinical implications
There is significant variation in the amount or rate of loss of
muscle mass in response to a range of diseases. In COPD,
skeletal atrophy appears to be a significant factor in about
25% of patients that can start early in the disease.3 In a sec-
ond example, we have recently shown that following major
cardiac surgery approximately 50% of patients will lose more
than 10% of their muscle mass in the following 7 days
whereas the others will not.46 Furthermore, there is marked
diversity in the response to treatment in patients with muscle
wasting with only a subset responding well to pulmonary re-
habilitation. This diversity hampers the development of
methodologies to improve muscle mass. Understanding the
basis for this variation in individual response to disease and
treatment will help to identify those at greatest risk of
wasting, to identify those likely to respond to therapies and
to develop novel targeted therapies. Our data here suggest
that expression levels of H19, miR-675, and the C19MC
miRNAs may contribute to this diversity of response and that
DNA methylation is a potential contributor to this differential
expression. It is possible therefore that measurement of
these factors may help to identify sub-groups of individuals
likely to respond differently to anabolic therapies.
Conclusions
Our data show that increased expression of miR-675 and H19
are associated with a low FFMI in patients with COPD. Fur-
thermore, increased expression of H19 is inversely correlated
with relative methylation of the H19 ICR. In male patients
with severe COPD, expression of the paternally expressed
C19MC miRNAs was suppressed in patients with a low FFMI.
We also confirmed that patients with a low FFMI had lower
levels of muscle regeneration than patients with a normal
FFMI. Together these data suggest that expression of
imprinted miRNAs may contribute to the susceptibility to a
low FFMI phenotype in COPD.
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